Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18773773 | 0.83 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22844076 | 0.83 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17776281 | 0.82 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL17776413 | 0.82 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL24513773 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21215234 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25413833 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21440828 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23289657 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21215354 | 0.81 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2023-01-05 | — | — | US | disclosed |
| WO-2018125992-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | PROMEGA CORPORATION (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | PCSK9, EGFR, PCSK6 | MEN1 3146/4885KMT2A 1058/4885SMN1; SMN2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.